westpharma3d1.jpg

Chris Evans: We are keen to improve user experience. One important topic in our industry is focusing around self-injection and self-therapy. The wearable business is getting larger and larger. With our SmartDose platform, we are a leader in the market. It offers a wearable, subcutaneous injector with an integrated drug delivery system that incorporates human factors and usability testing to deliver a truly patient-centric approach to self-administration. We make copies of that product as early as possible, to enable user tests, honing in on the best and most efficient workflow for the user and be able to put parts in patients’ hands as early as possible.

What future developments do you foresee?

Chris Evans: It all comes back to material development. There is continuous work to develop more realistic materials, and lots of work going on at universities. They have developed homemade machines that use cells and even printed ear for burn victim. It is possible to print prosthetics or metal and titanium alloys for joint implants. Material advancement is going to broaden the field, more products can be made, more materials are going to be approved by the FDA to be on/in the body. We see 3D printers become production machines for medical devices or parts that go into them. 

Brian Costello: I would like to reinforce one key point – the use of 3D printers as experimental tools. We embrace the technology, and different people in different areas/industries also embrace the technology. 3D printing builds a makers culture, and innovation processes cannot move forward without it.

More info:

www.westpharma.com